Thymosin Alpha-1 + BPC-157 Stack Protocol
The Thymosin Alpha-1 (TA1) + BPC-157 stack combines two well-characterized peptides that address immune function and tissue repair synergistically. TA1 (marketed as Zadaxin in 35+ countries) is a 28-amino acid thymic peptide that enhances T-cell maturation, NK cell cytotoxicity, dendritic cell function, and antibody responses. BPC-157 is a 15-amino acid gastric pentadecapeptide that accelerates tissue healing, reduces inflammation, and repairs the gut-immune barrier through VEGF upregulation and NO system modulation. Together, this stack supports comprehensive immune recovery alongside physical tissue repair, making it particularly valuable for post-illness recovery, immune rehabilitation, and chronic inflammatory conditions.
Protocol Overview
- Compounds
- Thymosin Alpha-1 (TA1) + BPC-157
- Category
- Immune Modulation / Tissue Repair Stack
- Mechanism
- TA1: T-cell maturation, NK activation, TLR agonism | BPC-157: VEGF, NO modulation, anti-inflammatory tissue repair
- Route
- Subcutaneous
- Frequency
- TA1: 2-3x/week | BPC-157: 1x daily
- Cycle Length
- 8-12 weeks on, 4-8 weeks off
Dosing Protocol
| Protocol | TA1 | BPC-157 | Frequency | Duration |
|---|---|---|---|---|
| Standard | 1.6 mg | 250 mcg | TA1 3x/wk + BPC daily | 8-12 weeks |
| Acute Immune | 1.6 mg | 250 mcg 2x | TA1 daily (7d) then 3x/wk + BPC 2x daily | 8-12 weeks |
| Maintenance | 1.6 mg | 250 mcg | TA1 2x/wk + BPC daily | 8-12 weeks |
Key principle: TA1 has a long biological duration of action (~7 days of immune modulation per dose), so 2-3x weekly dosing maintains consistent immune enhancement. BPC-157 benefits from daily dosing for sustained tissue repair signaling.
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site redness (mild)
- Mild flu-like symptoms during first week of TA1 (immune activation)
- Fatigue during initial immune reconstitution
Both peptides have extensive safety profiles. TA1 is approved in 35+ countries with decades of clinical use.
Precautions
- TA1: Avoid with organ transplant immunosuppression
- TA1: Caution with autoimmune conditions (may enhance immune activity)
- BPC-157: Theoretical concern with active cancer (angiogenesis)
- Not recommended during pregnancy
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Immune Panel | CD4/CD8 ratio, NK cell count, total lymphocytes | Baseline, Week 6, Week 12 |
| Inflammation | hs-CRP, ESR, IL-6, TNF-alpha | Baseline, Week 6, Week 12 |
| Liver Function | ALT, AST, GGT | Baseline, Week 12 |
| General | CBC with differential, CMP | Baseline, Week 6, Week 12 |
Related Tools & Resources
